-
Jefferies Downgrades NuVasive, Says M&A Unlikely To Materialize
Tuesday, February 12, 2019 - 11:21am | 360Read More...Shares of NuVasive, Inc. (NASDAQ: NUVA) spiked after the Financial Times named the company as a potential acquisition target. A deal seems unlikely and, even if a bid is received, there is little opportunity of it being higher than $60 per share, according to Jefferies. The Analyst Jefferies...
-
Adoption Of 3D Mammography Appears To Be On The Cusp Of An Inflection
Monday, March 13, 2017 - 9:59am | 341Read More...Jefferies’ Raj Denhoy believes the adoption of 3D mammography is on the verge of an inflection, stating that in the conversion from analog to 2D digital, “growth accelerated dramatically in year 7—exactly where we are in the 3D cycle.” The analyst maintained a Buy rating on...
-
Jefferies Cautions Investors: St. Jude Medical Device Issue Not Over Yet
Friday, September 9, 2016 - 3:01pm | 352Read More...Jefferies has warned that the storm hovering over St. Jude Medical, Inc. (NYSE: STJ) devices have not subsided yet, and in fact, there is likely more volatility to come. The brokerage met Dr. Hemal Nayak, an electrophysiologist working as a medical advisor on the board of MedSec, which found...
-
Jefferies Says Wright Medical A Top Pick, Management Meetings 'Heartening'
Friday, August 12, 2016 - 2:27pm | 284Read More...Wright Medical Group Inc (NASDAQ: WMGI) remains a Top Pick for Jefferies following a "heartening" meeting with management as the litigation concerns have overshadowed the company's strong underlying business. "There are few if any other companies in medtech with revenues of $...
-
Jefferies Likes Hologic For Zika, But Sees Blood Screening As Larger Opportunity
Monday, June 20, 2016 - 6:27pm | 179Read More...Hologic, Inc. (NASDAQ: HOLX) shares outperformed very modestly Monday following news the company and Grifols' Zika virus assay received FDA approval. The stock closed up nearly 1 percent versus a 0.73 percent rally in the Dow Jones Industrial Average and a 0.58 percent increase in the S&P...
-
Jefferies Upgrades Wright Medical To Buy: Next Year's Forecast Could Be Conservative
Monday, November 30, 2015 - 1:34pm | 240Read More...Shares of Wright Medical Group Inc (NASDAQ: WMGI) have declined 21.5 percent over the past six months, from $27.40 on May 29. Jefferies’ Raj Denhoy has upgraded the rating on the company from Hold to Buy, while raising the price target from $23 to $29. Denhoy believes that there...
-
Jefferies Reiterates Buy, Raises Price Target On Medtronic Following Very Good F3Q
Wednesday, February 18, 2015 - 10:35am | 104Read More...In a report published Wednesday, Jefferies analyst Raj Denhoy reiterated a Buy rating on Medtronic PLC (NYSE: MDT), and raised the price target from $83.00 to $89.00. In the report, Jefferies noted, "MDT posted a very good F3Q, highlighted by: strength in CRDM, where the US quadpole launch is...
-
UPDATE: Jefferies Reiterates On Unilife Corp On Potential For Commercial Sales
Wednesday, September 10, 2014 - 9:03am | 98Read More...In a report published Wednesday, Jefferies analyst Raj Denhoy reiterated a Buy rating on Unilife Corp (NASDAQ: UNIS), but lowered the price target from $6.00 to $5.00. In the report, Jefferies noted, “4Q was a Q of significant spending and little underlying commercial activity. The near-term should...
-
UPDATE: Jefferies Reiterates on Medtronic Following Mixed F2Q Results
Wednesday, November 20, 2013 - 11:36am | 102Read More...In a report published Wednesday, Jefferies analyst Raj Denhoy reiterated a Hold rating on Medtronic (NYSE: MDT), and raised the price target from $56.00 to $60.00. In the report, Jefferies noted, “Medtronic posted mixed F2Q results, highlighted by a meaningful recovery in ICDs, continued InFUSE...
-
UPDATE: Jefferies Raises PT on Accuray Following Good F4Q Results
Wednesday, August 28, 2013 - 9:27am | 102Read More...In a report published Wednesday, Jefferies analyst Raj Denhoy reiterated a Buy rating on Accuray (NASDAQ: ARAY), and raised the price target from $6.50 to $8.00. In the report, Jefferies noted, “ARAY posted a good F4Q with a modest revenue beat, tighter expense controls, and another sequential...
-
UPDATE: Jefferies Raises PT on Medtronic Following Disappointing F1Q Results
Wednesday, August 21, 2013 - 11:02am | 108Read More...In a report published Wednesday, Jefferies analyst Raj Denhoy reiterated a Hold rating on Medtronic (NYSE: MDT), and raised the price target from $53.00 to $56.00. In the report, Jefferies noted, “F1Q results were below expectations, driven by weakness in ICDs, Core Spine, Neuro, and Diabetes,...
-
UPDATE: Jefferies Raises PT on DexCom Following Strong 2Q Results
Thursday, August 8, 2013 - 10:42am | 91Read More...In a report published Thursday, Jefferies analyst Raj Denhoy reiterated a Buy rating on DexCom (NASDAQ: DXCM), and raised the price target from $21.00 to $27.00. In the report, Jefferies noted, “DXCM put up a strong 2Q with product revenues +65% on uptake of G4 and guidance was raised by $10mm...
-
UPDATE: Jefferies Initiates Kamada at Buy on Solid Foundation
Tuesday, June 25, 2013 - 11:13am | 117Read More...In a report published Tuesday, Jefferies analyst Raj Denhoy initiated coverage on Kamada (NASDAQ: KMDA) with a Buy rating and $15.00 price target. In the report, Jefferies noted, “Kamada's core plasma protein extraction and distribution businesses provide a solid foundation but the investment...
-
UPDATE: Jefferies Raises PT on Cyberonics Following Management Meetings
Wednesday, June 12, 2013 - 11:31am | 115Read More...In a report published Wednesday, Jefferies analyst Raj Denhoy reiterated a Buy rating on Cyberonics (NASDAQ: CYBX), and raised the price target from $59.00 to $60.00. In the report, Jefferies noted, “Cyberonics is firing on all cylinders in epilepsy, which should drive strong and sustainable...
-
UPDATE: Jefferies Lowers PT on Cyberonics Following CMS Rejection
Wednesday, May 29, 2013 - 9:28am | 102Read More...In a report published Wednesday, Jefferies analyst Raj Denhoy reiterated a Buy rating on Cyberonics (NASDAQ: CYBX), but lowered the price target from $58.00 to $49.00. In the report, Jefferies noted, “CMS formally rejected Cyberonics' request for reconsideration of its non-coverage policy for...
